Director Brian Stuglik (VSTM) awarded 36,000 Verastem RSUs with 2026–2027 vesting

Rhea-AI Filing Summary

Stuglik Brian M reported acquisition or exercise transactions in this Form 4 filing.

Verastem, Inc. director Brian M. Stuglik received an equity grant of 36,000 restricted stock units (RSUs) of Common Stock. The RSUs were granted at no cash cost as director compensation and will vest in twelve substantially equal monthly installments from late June 2026 through April 2027, with the final installment vesting on the earlier of the day before the 2027 Annual Meeting of Stockholders or May 31, 2027, subject to continued board service. Following this award, Stuglik holds 137,147 shares of Verastem Common Stock directly.

Insights

Equity Compensation Analyst

Routine RSU grant to Verastem director with time-based vesting.

Director Brian M. Stuglik received 36,000 RSUs of Verastem Common Stock as part of the company’s Amended and Restated 2021 Equity Incentive Plan. The grant price is listed as $0.0000 per share, consistent with a compensatory award rather than a market purchase.

The RSUs vest in twelve substantially equal installments from June 2026 through April 2027, with a final tranche vesting by May 31, 2027, conditioned on continued board service. This time-based structure aligns director incentives with ongoing oversight, but does not reflect an open-market buy or sell decision.

After the grant, Stuglik directly holds 137,147 shares. With no derivative positions reported in this filing and no sales activity, the transaction appears as a standard, compensation-related equity award, typically viewed as administratively neutral from an investment thesis standpoint.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Stuglik Brian M

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	36,000	$0.00	--

Holdings After Transaction: Common Stock — 137,147 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 36,000 RSUs Grant price per share: $0.0000 per share Total shares after grant: 137,147 shares +2 more

5 metrics

RSU grant size 36,000 RSUs Awarded to director Brian M. Stuglik

Grant price per share $0.0000 per share Compensatory RSU award, not cash purchase

Total shares after grant 137,147 shares Common Stock directly owned after transaction

Vesting installments 12 installments Monthly vesting June 2026 to April 2027 plus final 2027 tranche

Final vesting outside date May 31, 2027 Latest possible date for last RSU installment

Key Terms

RSUs, Amended and Restated 2021 Equity Incentive Plan, contingent right, vest, +1 more

5 terms

RSUs financial

"RSUs granted to the Reporting Person under the Issuer's Amended and Restated 2021 Equity Incentive Plan."

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

Amended and Restated 2021 Equity Incentive Plan financial

"RSUs granted to the Reporting Person under the Issuer's Amended and Restated 2021 Equity Incentive Plan."

contingent right financial

"Each RSU represents the contingent right to receive one share of Common Stock."

vest financial

"The RSUs vest in twelve substantially equal installments (rounded down to the nearest whole share on each vesting date..."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

Annual Meeting of Stockholders financial

"the day before the 2027 Annual Meeting of Stockholders is held or (ii) May 31, 2027"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stuglik Brian M

(Last) (First) (Middle)

C/O VERASTEM, INC.,

117 KENDRICK ST., SUITE 500

(Street)

NEEDHAM MASSACHUSETTS 02494

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Verastem, Inc. [ VSTM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/21/2026		A		36,000(1)	A	$0.00	137,147	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. RSUs granted to the Reporting Person under the Issuer's Amended and Restated 2021 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve substantially equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2026 to April, 2027 and the last installment shall vest on the earlier of (i) the day before the 2027 Annual Meeting of Stockholders is held or (ii) May 31, 2027, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date.

	/s/ Daniel Calkins, Attorney in Fact	05/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Verastem (VSTM) director Brian M. Stuglik report in this Form 4?

Brian M. Stuglik reported receiving a grant of 36,000 restricted stock units of Verastem Common Stock. These RSUs were awarded under the company’s Amended and Restated 2021 Equity Incentive Plan as compensation, not as an open-market purchase of shares.

How many Verastem (VSTM) RSUs were granted to Brian M. Stuglik and at what price?

Brian M. Stuglik was granted 36,000 restricted stock units of Verastem Common Stock at a reported price of $0.0000 per share. This indicates a compensatory equity award rather than a cash-funded stock purchase in the open market.

What is the vesting schedule for Brian M. Stuglik’s Verastem (VSTM) RSU grant?

The 36,000 RSUs vest in twelve substantially equal installments from June 2026 through April 2027. The final installment vests on the earlier of the day before the 2027 Annual Meeting of Stockholders or May 31, 2027, if he continues serving as a director.

What conditions must be met for Brian M. Stuglik’s Verastem (VSTM) RSUs to vest?

The RSUs require that Brian M. Stuglik continue serving as a Verastem director on each vesting date. If he remains on the board through the schedule, all twelve installments, including the final tranche in 2027, will convert into Common Stock shares.

How many Verastem (VSTM) shares does Brian M. Stuglik hold after this RSU award?

Following the RSU grant, Brian M. Stuglik is reported to directly own 137,147 shares of Verastem Common Stock. This total reflects his holdings after accounting for the 36,000-share RSU award disclosed in the Form 4 filing.

Are Brian M. Stuglik’s Verastem (VSTM) RSUs equivalent to common shares when vested?

Each RSU represents the contingent right to receive one share of Verastem Common Stock upon vesting. As installments vest under the schedule, the corresponding RSUs convert into an equal number of common shares, assuming service conditions are satisfied.